Yasin Keshvargar

Davis Polk advised the underwriter in connection with an SEC-registered secondary offering of 1,400,000 shares of Veritiv Corporation’s common stock by UWW Holdings, LLC. The common…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Davis Polk advised the representative of the initial purchasers in connection with the debut Rule 144A/Regulation S offering by LD Holdings Group LLC of $500 million aggregate principal…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Energizer Holdings, Inc. of $800 million aggregate principal…

 Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of…